Larotinib/Larotinib contraindications and precautions

Larotrectinib is the world's first highly selective TRK inhibitor specifically designed to treat NTRK gene fusion-positive solid tumors. This "organ-free" targeted therapy has changed the traditional classification of cancer treatment according to the organ of onset, and is especially suitable for rare tumors derived from multiple tissues. Although larotrectinib is widely praised for its mild side effects and good tolerance, there are still several contraindications and precautions during its use, and patients and doctors should pay special attention to it during practical application.

First, the most critical contraindication is that patients who are allergic to the active ingredient of larotrectinib or any of its excipients should not use it. Anaphylaxis may manifest as rash, dyspnea, laryngeal edema, or anaphylactic shock. Although this is extremely rare, the consequences are serious if it occurs, so the allergy history should be fully evaluated before first use of the drug.

Second, larotrectinib needs to be used with extreme caution in patients with severe hepatic dysfunction. This drug is mainly metabolized by the liver in the body. Severe liver damage will affect its metabolic clearance, leading to an increase in blood drug concentration and increasing the risk of toxic and side effects. In this case, doctors usually make dosage adjustments based on the patient's Child-Pugh score, or decide whether to continue use after weighing the pros and cons. In addition, liver function indicators, especially ALT and AST, need to be monitored regularly during treatment to detect potential liver toxicity in a timely manner.

Thirdly, although pediatric patients are one of the potential candidates for larotrectinib, special attention should be paid to the dosage and the impact on growth and development when using it. Although foreign studies have confirmed that its application in pediatric patients is effective, more follow-up studies are still needed on reproductive system development and long-term safety.

In summary, although larotrectinib is a precisely targeted drug, its safe use still requires strict individualized evaluation and dynamic monitoring. Patients should truthfully inform them of their past medical history and other drugs they are taking before starting treatment, so that doctors can formulate the most appropriate treatment plan and maintain regular review during the medication period to ensure maximum treatment benefit and minimum risk of toxicity.

Reference materials:https://www.vitrakvi.com/